NO934320L - T celle reseptor peptider som terapeutiske midler for immum-relaterte sykdommer - Google Patents

T celle reseptor peptider som terapeutiske midler for immum-relaterte sykdommer

Info

Publication number
NO934320L
NO934320L NO934320A NO934320A NO934320L NO 934320 L NO934320 L NO 934320L NO 934320 A NO934320 A NO 934320A NO 934320 A NO934320 A NO 934320A NO 934320 L NO934320 L NO 934320L
Authority
NO
Norway
Prior art keywords
immune
cell receptor
therapeutic agents
related diseases
tcr
Prior art date
Application number
NO934320A
Other languages
English (en)
Norwegian (no)
Other versions
NO934320D0 (no
Inventor
Arthur Allen Vandenbark
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Publication of NO934320D0 publication Critical patent/NO934320D0/no
Publication of NO934320L publication Critical patent/NO934320L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO934320A 1991-05-31 1993-11-29 T celle reseptor peptider som terapeutiske midler for immum-relaterte sykdommer NO934320L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70802291A 1991-05-31 1991-05-31
US73561291A 1991-07-16 1991-07-16
PCT/US1992/004492 WO1992021367A1 (fr) 1991-05-31 1992-06-01 Peptides recepteurs de lymphocytes t utilises comme agents therapeutiques contre des maladies du systeme immunitaire

Publications (2)

Publication Number Publication Date
NO934320D0 NO934320D0 (no) 1993-11-29
NO934320L true NO934320L (no) 1994-01-27

Family

ID=27108005

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934320A NO934320L (no) 1991-05-31 1993-11-29 T celle reseptor peptider som terapeutiske midler for immum-relaterte sykdommer

Country Status (11)

Country Link
EP (1) EP0587735B1 (fr)
JP (1) JPH07502977A (fr)
AT (1) ATE189230T1 (fr)
AU (1) AU674494B2 (fr)
CA (1) CA2110055C (fr)
DE (1) DE69230612T2 (fr)
DK (1) DK0587735T3 (fr)
ES (1) ES2144418T3 (fr)
GR (1) GR3033318T3 (fr)
NO (1) NO934320L (fr)
WO (1) WO1992021367A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667967A (en) * 1990-05-01 1997-09-16 The Board Of Trustees Of The Leland Stanford Junior University T-cell receptor varible transcripts as disease related markers
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
EP0674661B1 (fr) * 1992-12-18 2003-07-02 Molecular Rx., Inc. Titrage et traitement destines aux maladies demyelinisantes telles que la sclerose en plaques
GB9308581D0 (en) * 1993-04-26 1993-06-09 Univ Manitoba A method for induction of antigen-specific suppression of immune-response
AU6376194A (en) * 1993-05-14 1994-12-12 Dr. L. Willems-Instituut Human t cell monoclone, process for its production and its use, diagnostic of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer
AU695801B2 (en) * 1993-09-22 1998-08-20 Board Of Trustees Of The Leland Stanford Junior University Interaction of T-cell receptors and antigen in autoimmune disease
US5552300A (en) * 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
AU721898B2 (en) 1994-11-18 2000-07-20 Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
WO1996028470A2 (fr) * 1995-03-09 1996-09-19 Neurocrine Biosciences, Inc. Analogues peptidiques de proteine de base de myeline utile dans le traitement de la sclerose en plaques
IL113159A0 (en) * 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
AU2651997A (en) * 1996-05-10 1997-12-05 Kirin Beer Kabushiki Kaisha T-cell receptor alpha-chain constant-region peptides, processes for producing the peptides, and use thereof
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
EP2050814A1 (fr) 2007-10-17 2009-04-22 Txcell Compositions pour traiter la sclérose en plaque
EP3122768A2 (fr) * 2014-03-27 2017-02-01 Yeda Research and Development Co. Ltd. Récepteur de cellules t cdr3, peptides et anticorps

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886743A (en) * 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
CA2046909A1 (fr) * 1989-03-21 1990-09-22 Mark D. Howell Vaccination et methodes d'immunisation contre les maladies resultant de reactions pathogenes provoquees par des populations de lymphocytes t
JP3072330B2 (ja) * 1989-07-19 2000-07-31 ジ・イミューン・レスポンス・コーポレーション 自己免疫疾患および悪性疾患の治療のためのｔ細胞リセプターペプチド
EP0568623A1 (fr) * 1991-01-22 1993-11-10 The Immune Response Corporation Vaccination et procedes de lutte contre des maladies causees par des reactions pathogenes de populations de lymphocytes t

Also Published As

Publication number Publication date
EP0587735A4 (fr) 1995-05-03
CA2110055A1 (fr) 1992-12-10
DE69230612T2 (de) 2000-06-21
ES2144418T3 (es) 2000-06-16
GR3033318T3 (en) 2000-09-29
AU674494B2 (en) 1997-01-02
EP0587735A1 (fr) 1994-03-23
NO934320D0 (no) 1993-11-29
JPH07502977A (ja) 1995-03-30
DE69230612D1 (de) 2000-03-02
DK0587735T3 (da) 2000-09-11
CA2110055C (fr) 2002-08-20
AU2147292A (en) 1993-01-08
EP0587735B1 (fr) 2000-01-26
ATE189230T1 (de) 2000-02-15
WO1992021367A1 (fr) 1992-12-10

Similar Documents

Publication Publication Date Title
NO920252D0 (no) T celle-reseptor peptider som legemiddel for autoimmun ogmalign sykdom
Schnell et al. Recombinant rabies virus as potential live-viral vaccines for HIV-1
DK0587735T3 (da) T-cellereceptorpeptider som terapeutiske midler til immunrelateret sygdom
DK0702563T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme
EP0330227A3 (fr) Dérivés de T-4 solubles
NO941986L (no) Anti-kreft immunoterapeutisk vektorkonstruksjoner
EP0545016A1 (fr) Composition pour le transfert de complexes d'acide nucléqiue chez les cellules encaryotes supérieures
EA200300824A1 (ru) Тиенил-, фурил-, пирролил- и дифенилсульфонамиды и их производные, модулирующие активность эндотелина
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
Cronkite et al. Mechanism of protective action of glutathione against whole body irradiation.
DE69706593D1 (de) Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier
ES8501980A1 (es) Un procedimiento para la preparacion de una vacuna contra picornavirus.
NO943653L (no) Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon
DE3751319D1 (de) VERWENDUNG UND ZUSAMMENSETZUNG ZUR VERBESSERUNG DES "TARGETING" VON ANTIKöRPERN, ANTIKöRPERTEILEN, SOWIE KONJUGATE DERSELBEN.
DE3787477D1 (de) Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung.
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
NO931413L (no) Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer
AU5158000A (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
AU3991899A (en) Verotoxin b subunit for immunization
ES8302457A1 (es) Un procedimiento para preparar soluciones acu0sas a base de una sal de sulfonamida acuosoluble, un potenciador de sulfo-namida y un aldehido.
Urquhart et al. Trial of high-titre human rubella immunoglobulin.
Inoue et al. Protective effects of anti-glycoprotein D monoclonal antibodies in murine herpetic keratitis
AU8501191A (en) Cross-reactive influenza a immunization
SE9402332D0 (sv) Igf-1
北原糺 Molecular mechanisms of vestibular compensation